MCIM
CYTK icon

Meadow Creek Investment Management’s Cytokinetics CYTK Stock Holding History

Meadow Creek Investment Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$84K Hold
7,344
– – ﹤0.01% 1229
2019
Q2 		$83K Hold
7,344
– – ﹤0.01% 1243
2019
Q1 		$59K Buy
7,344
+2,416
+49% +$17.8K ﹤0.01% 1255
2018
Q4 		$31K Buy
4,928
+1,760
+56% +$12.9K ﹤0.01% 1239
2018
Q3 		$31K Buy
3,168
+1,488
+89% +$11.9K ﹤0.01% 1289
2018
Q2 		$14K Buy
+1,680
New +$14K ﹤0.01% 1296

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Meadow Creek Investment Management's CYTK Position: Q3 2019 in Review

Meadow Creek Investment Management held its Cytokinetics (CYTK) position steady in Q3 2019 at 7,344 shares worth $84K. The position accounts for ﹤0.01% of the portfolio, ranked #1229.

Meadow Creek Investment Management first reported a position in CYTK in Q2 2018 and has held it in 6 quarters since. 148 funds tracked by Wall St. Rank hold CYTK as of Q3 2019.

  • Meadow Creek Investment Management held 7,344 shares of Cytokinetics worth $84K as of Q3 2019.
  • Meadow Creek Investment Management left its Cytokinetics share count unchanged in Q3 2019.
  • Cytokinetics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1229 holding.
  • Meadow Creek Investment Management first reported a position in Cytokinetics in Q2 2018 and has held it in 6 quarters since.
  • 148 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.